Literature DB >> 23745567

Multimodality imaging of RNA interference.

T R Nayak1, L K Krasteva, W Cai.   

Abstract

The discovery of small interfering RNAs (siRNAs) and their potential to knock down virtually any gene of interest has ushered in a new era of RNA interference (RNAi). Clinical use of RNAi faces severe limitations due to inefficiency delivery of siRNA or short hairpin RNA (shRNA). Many molecular imaging techniques have been adopted in RNAi-related research for evaluation of siRNA/shRNA delivery, biodistribution, pharmacokinetics, and the therapeutic effect. In this review article, we summarize the current status of in vivo imaging of RNAi. The molecular imaging techniques that have been employed include bioluminescence/fluorescence imaging, magnetic resonance imaging/ spectroscopy, positron emission tomography, single-photon emission computed tomography, and various combinations of these techniques. Further development of non-invasive imaging strategies for RNAi, not only focusing on the delivery of siRNA/shRNA but also the therapeutic efficacy, is critical for future clinical translation. Rigorous validation will be needed to confirm that biodistribution of the carrier is correlated with that of siRNA/shRNA, since imaging only detects the label (e.g. radioisotopes) but not the gene or carrier themselves. It is also essential to develop multimodality imaging approaches for realizing the full potential of therapeutic RNAi, as no single imaging modality may be sufficient to simultaneously monitor both the gene delivery and silencing effect of RNAi.

Entities:  

Mesh:

Year:  2013        PMID: 23745567      PMCID: PMC3749287          DOI: 10.2174/0929867311320290012

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  116 in total

1.  Generation and characterization of bioluminescent xenograft mouse models of MLL-related acute leukemias and in vivo evaluation of luciferase-targeting siRNA nanoparticles.

Authors:  Raffaella Fazzina; Lorenza Lombardini; Laura Mezzanotte; Aldo Roda; Patrizia Hrelia; Andrea Pession; Roberto Tonelli
Journal:  Int J Oncol       Date:  2012-05-31       Impact factor: 5.650

2.  A definition of molecular imaging.

Authors:  David A Mankoff
Journal:  J Nucl Med       Date:  2007-06       Impact factor: 10.057

3.  In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier.

Authors:  Broes Naeye; Hendrik Deschout; Vicky Caveliers; Benedicte Descamps; Kevin Braeckmans; Christian Vanhove; Jo Demeester; Tony Lahoutte; Stefaan C De Smedt; Koen Raemdonck
Journal:  Biomaterials       Date:  2012-12-20       Impact factor: 12.479

4.  Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.

Authors:  Snehal M Gaikwad; Pritha Ray
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

5.  Image-guided breast tumor therapy using a small interfering RNA nanodrug.

Authors:  Mohanraja Kumar; Mehmet Yigit; Guangping Dai; Anna Moore; Zdravka Medarova
Journal:  Cancer Res       Date:  2010-08-11       Impact factor: 12.701

6.  Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.

Authors:  Kristen Bisanz; Jie Yu; Magnus Edlund; Bill Spohn; Mien-Chie Hung; Leland W K Chung; Chia-Ling Hsieh
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

7.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

8.  Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment.

Authors:  Hao Hong; Yin Zhang; Hakan Orbay; Hector F Valdovinos; Tapas R Nayak; Jero Bean; Charles P Theuer; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2013-01-14       Impact factor: 4.939

9.  Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Authors:  Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

10.  Activation of the interferon system by short-interfering RNAs.

Authors:  Carol A Sledz; Michelle Holko; Michael J de Veer; Robert H Silverman; Bryan R G Williams
Journal:  Nat Cell Biol       Date:  2003-08-24       Impact factor: 28.824

View more
  2 in total

Review 1.  Imaging-guided delivery of RNAi for anticancer treatment.

Authors:  Junqing Wang; Peng Mi; Gan Lin; Yì Xiáng J Wáng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-01-22       Impact factor: 15.470

Review 2.  Nano-based delivery of RNAi in cancer therapy.

Authors:  Yong Xin; Min Huang; Wen Wen Guo; Qian Huang; Long Zhen Zhang; Guan Jiang
Journal:  Mol Cancer       Date:  2017-07-28       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.